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NANOPARTIKEL OKSIDA BESI SEBAGAI PENGGALAK DOS 
RADIOBIOLOGI UNTUK RADIOTERAPI 
 
ABSTRAK 
Pengenalan: Nanopartikel oksida besi (IONPs) telah dikaji secara meluas sebagai agen 
kontras untuk pengimejan resonans magnet (MRI) dan lain-lain aplikasi bioperubatan 
yang berpotensi seperti penyampaian ubat yang disasarkan. Sifat-sifat IONPs yang 
menarik bukan sahaja berpotensi untuk multimodaliti aplikasi diagnostik tetapi juga 
untuk kegunaan terapeutik terutamanya radioterapi. Di dalam tesis ini, potensi aplikasi 
IONPs dalam meningkatkan kecekapan hasil radioterapi telah disiasat dan diterokai.  
Kaedah: Kajian ini dijalankan secara in-vitro menggunakan T24 sel kanser pundi 
kencing, HCT116 sel karsinoma kolon manusia dan F98 sel glioma tikus bersama 15nm 
IONPs. Pada mulanya penilaian ketoksikan dijalankan untuk memastikan IONPs serasi 
terhadap sel.  Penyiasatan terhadap penggalakan dos telah dijalankan dengan 
meradiasikan sel yang terkandung dan tidak mengandungi 1mMol/L IONPs 
menggunakan pancaran foton, elektron, proton dan sinkrotron kilovolt monoenergetik 
sinar-x yang mempunyai tenaga dan dos yang berbeza. Lekuk kemandirian sel telah 
diperolehi menggunakan piawaian pengklonian asei dan dianalisis menggunakan LQ 
model. Faktor penggalakan dos diekstrapolasi sebanyak 90% daripada kemandirian sel 
dan dikira daripada lekukan yang terbentuk.   
Keputusan dan perbincangan: Ujian ketoksikan menunjukkan in vitro serasi terhadap 
IONPs. Pemerhatian terhadap IONPs mendapati peningkatan ke atas kesan penggalakan 
dos bagi semua pancaran yang diuji kecuali pancaran elektron. Pancaran foton dengan 
tenaga 6 MV dan 10 MV menunjukkan peningkatan dos sebanyak 1.71 – 2.50 dengan 
kehadiran IONPs. Sementara itu, pancaran ion berat proton dengan LET tinggi 
 xiv 
 
menunjukkan faktor penggalakan dos menghampiri 2 kali ganda. Pancaran sinkrotron 
kilovolt monoenergetik sinar-x menunjukkan peningkatan dos yang paling tinggi 
dengan nilai DEF sebanyak 9.11. Walaubagaimanapun, iradiasi menggunakan pancaran 
elektron tidak mengemukakan sebarang kesan penggalakan dos yang mana boleh 
menjadi kaitan dengan kekurangan interaksi yang mendorong radikal bebas dan spesies 
oksigen reaktif (ROS) yang menggalakkan kematian sel.  
Kesimpulan: IONPs didapati berkesan sebagai penggalak dos untuk rawatan kanser 
menggunakan sinaran mengion dari segi jenis dan tenaga yang berbeza kecuali terapi 
pancaran elektron. Kesan yang lebih ketara dapat dilihat dengan menggunakan pancaran 
sinkrotron kilovolt monoenergetik sinar-x dan pancaran proton dan mencadangkan ia 
sebagai teknik aplikasi klinikal yang baru untuk IONPs. Keberkesanan penggunaan 
IONPs di dalam radioterapi kanser dan juga pengimejan diagnostik boleh memberi 
petunjuk ke arah aplikasi kanser teranostik yang lebih maju pada masa hadapan.  
Kata kunci: nanopartikel oksida besi, penggalak dos, radioterapi 
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IRON OXIDE NANOPARTICLES AS RADIOBIOLOGICAL DOSE 
ENHANCER FOR RADIOTHERAPY 
 
ABSTRACT 
Introduction: Iron oxide nanoparticles (IONPs) have extensively been investigated as 
contrast agents for magnetic resonance imaging (MRI) and other promising biomedical 
application such as targeted drug delivery. The intriguing properties of IONPs not only 
promising for multimodality diagnostic application but also for therapeutic purpose 
especially radiotherapy. In this thesis, potential application of IONPs to increase the 
efficiency of radiotherapy outcome was investigated and explored.    
Methods: The study is conducted in-vitro using T24 bladder cancer cells, HCT116 
human colon carcinoma cell lines and F98 rat glioma cells with 15 nm IONPs. The 
evaluation on the cytotoxicity was initially conducted to ensure the IONPs 
biocompatibility to the cells. Investigation on the dose enhancement were done by 
irradiating the cells with and without 1mMol/L of IONPs using photon, electron, proton 
and synchrotron’s kilovoltage monoenergetic x-rays beams of different energies and 
doses. The cell survival curves were obtained using standard clonogenic assay and were 
analyzed using linear quadratic model. Dose enhancement factor (DEF) were 
extrapolated at 90% cell survival and calculated from the survival curves.  
Results and discussions: Cytotoxicity test indicate in vitro biocompatibility of IONPs. 
IONPs were observed to induce dose enhancement effects in all different types of 
radiotherapy beam tested except the electron beam. Photon beam of energy 6 MV and 
10 MV show dose enhancements of 1.71-2.50 folds in the presence IONPs. Meanwhile, 
the high LET heavy ion of proton beam indicate higher enhancement factor closed to 2 
fold. Synchrotron’s kilovoltage monoenergetic x-rays beam indicates highest dose 
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enhancement effects with DEF value 9.11. However, irradiation with electron beams 
does not produce any significant dose enhancement effects which could be link to the 
lack of interaction that induce free radical and reactive oxygen species (ROS) that 
enhance the cell’s death.   
Conclusions: The IONPs are found to be effective as dose enhancer for cancer 
treatment using different types of ionizing radiation and energy ranges except for 
electron beam therapy. The effects are more pronounced for synchrotron kilovoltage 
monoenergetic x-rays beam and proton beam suggesting the potential new technique for 
IONPs clinical application. The outcome from this thesis implying the clinical potential 
of IONPs in increasing the radiotherapy efficiency to treats cancer.  
Keywords: iron oxide nanoparticles, dose enhancement, radiotherapy 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Radiotherapy 
Radiotherapy is one of the critical techniques in the cancer treatment and 
management that employ ionizing radiation to produce the lethal effects to the 
malignant cells. Patients diagnosed with cancer are often referred to radiotherapy as 
part of their treatment regime (Hoskin, P., 2006). Bombardments of ionizing 
radiation to the tumour or target are highly localized and conformal which could 
deliver sufficient dose to kill tumour cell and concurrently prevent dose to the 
surrounding normal tissue. Uniformly distributed radiation dose to the tumours are 
also highly aided by the advanced imaging and treatment planning system (Levin, et 
al., 2005).Therefore radiotherapy remains the most important non-surgical treatment 
of cancer. 
Modern approach of radiotherapy that applied for curative and adjuvant 
cancer treatment is fundamentally dependent on the concept that radiation induced 
DNA damage to the cells. Crippling cell growth and mitosis from the damage shrinks 
the tumours and prevent metastasis. However, it is still a challenge to completely 
avoid surrounding normal tissue when delivering radiation dose to the tumours. 
Mechanism of highly conformal treatment are usually delivered through external 
beam radiotherapy (EBRT) technique  or it may come from radioactive material 
placed in the body near the tumour cells or injected into the bloodstream (internal 
beam radiotherapy, also called brachytherapy). 
EBRT mainly utilizes linear accelerator (LINAC) that equips with beam 
shaping component such multileaf collimator to increase the specificity towards the 
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target volume. High energy photon beam of the range from 6 to 25 MV are widely 
and commonly used to treat many type of cancer especially the deep seated tumours 
(Hoskin, P., 2006). LINAC also produce electron beam to treat superficial and sub 
surface cancer. Conformity and targeting capabilities of the EBRT have been going 
through much improvement with applicability of advance technique such as intensity 
modulated radiotherapy and image guided radiotherapy.    
Augmenting the therapeutic efficiency of radiotherapy is a huge challenge 
due to diverse nature of cancer. Different treatment techniques are being developed 
to cater the needs of treating malignancy while preserving the surrounding normal 
tissue. Conventional LINAC based radiotherapy provides excellent tumour control 
but sometimes unnecessary exposure to normal tissue cannot be avoided. This is a 
concern for paediatric patients which has high probability to develop complication 
and secondary malignancy. Particle beam radiotherapy stimulates interest due to their 
superior dose distribution compare to photon (Levin, et al., 2005). Distinctive 
characteristic of particles beam produce another excellent alternative for cancer 
treatment. Figure 1.1 shows different type of radiation used in radiotherapy.     
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Figure 1.1: Type of radiation used in radiotherapy 
 
 
1.1.1 Photon Beam Radiotherapy 
Conventional radiotherapy mostly utilize photon beam to treat various type of 
cancer. Photon beam in the form of x-ray or gamma ray is used to achieve tumour 
control by inducing DNA damage to the cancerous cells. The cellular damage 
increase proportionally with radiation dose that represent the amount of energy that 
the ionizing radiation deposits (Trikalinos, et al., 2009; Peter Hoskin, 2006).The 
sources of photon beam usually originate from LINAC which is the most commonly 
used beam delivery device for radiotherapy. Meanwhile treatments with gamma ray 
are normally done using the gamma emitting radioisotope such as Co-60.   
Figure 1.2 shows the basic components of LINAC in production of high-
energy photon beams.  
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Figure 1.2: Basic components of linear accelerator 
 
High energy photon beam produced by medical LINAC are yielded when 
electron from accelerator guide smashed into heavy metal target.  The electron 
originated from the heated filament will travel through accelerator waveguide to 
acquire the required kinetic energy from the radiofrequency power source. The 
electron beam will then go through the electron beam transport system in which the 
beam is focused through the angle between 90° and 270° before hitting the target. 
The high energy photon or x-ray produced from the target need to be tuned to ensure 
uniform intensity and homogenous dose distribution. Uniform dose distribution and 
homogenous dose variation will ease the treatment planning and dose calculation to 
the patient. This is usually being achieved by having flattening filter in LINAC 
which is normally located between the primary collimator and the monitor chamber. 
The flattening filter is made off high atomic number (Z) material and conical in 
shape to flatten the forward peaked bremsstrahlung spectrum of megavoltage photon 
beams (Sharma, 2011). The flat dose profile of photon beam will then be collimated 
using jaws collimator and multileaf collimator (MLC) to produce clinically useful 
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beam to treat various type of cancer. In the advance technique, the intensity of the 
photon beam will be modulated so that much more conform dose to the tumour is 
produce without hitting critical adjacent organs.  
Ability to penetrate deeper into human tissues granting the popularity of 
megavoltage photon beam in treating majority of deep seated tumours in patients. 
The usefulness of the photon beam depends on their energy and volume to be treated. 
Versatility in term of beam choice and excellent skin sparing effects give major 
advantages for high energy LINAC based radiotherapy compare to earlier version of 
radiotherapy using kilovoltage x-rays and Co-60 teletherapy unit. Megavoltage 
photon beams exhibit low surface dose, maximum dose at depth, gradual loss of dose 
with depth and sharp physical penumbra at the beam edge. Photon beams with higher 
energy show reduced attenuation compare to lower energy photon beams. 
Meanwhile, the maximum dose of kilovoltage beams occurs at the surface giving 
unnecessary skin dose. Therefore, kilovoltage beams are typically only useful for 
treatment superficial lesions. Photon energies < 150 keV are limited to lesions with 
thickness < 0.5 cm due to rapid dose fall off. Orthovoltage treatments usually limited 
to < 2 cm lesions thickness.  Beam energy also determined the rate of dose fall. Dose 
falloff is sharper for high energy beams. Compare to kilovoltage beams, megavoltage 
beams have very sharp penumbra at the surface.  
  In order to achieve uniform dose distribution, photon beam radiotherapy was 
carried out by cross firing multiple beams towards the target volume.  Beam 
configurations are designed and planned to deliver homogenous dose to the tumours 
while ensuring normal tissue receive minimal dose as possible. Current modern 
radiotherapy planning system provide visualisation of dose distribution that assist in 
more effective cancer treatment. 
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1.1.2 Electron Beam Radiotherapy 
Electron beam used in radiotherapy is commonly produced by similar 
medical LINAC that generates photon beams. It is widely available at radiotherapy 
center with energy ranging from 6 to 25 MeV and the application are popular for 
superficial types of malignant and diseases. The method used in the production 
clinically useful electron beam is different from photons production. Electron beams 
used for treatment can be produced by rapidly scanning the narrow beam of electrons 
that originate directly from the electron gun and accelerator waveguide. The pencil 
beam electron was then broadened using the scattering foils. The thin metal sheets 
scattered the electron beam, thereby expanding the useful size of the therapy beam. 
The broadened electron beam is collimated to appropriate size for treatment using 
lower and upper jaws and additional electron collimators known as electron cones. A 
series of openings in an electron applicator are used to collimate the beam at or close 
to patient’s skin (Stanton, et al., 1996). The field size of the electron beams were 
determined by the applicator’s size (Ajjitchandran, 2008). 
In comparison to photon beam, electron are subatomic particle that loss 
energy continuously when they interact with matter. The electrons interact with 
atoms by variety of processes when its travel through medium. The processes occurs 
are inelastic collision with atomic electrons (ionization and excitation), inelastic 
collisions with nuclei (bremsstrahlung), elastic collisions with atomic electrons and 
elastic collisions with nuclei. The electron will lose their energy when they travel 
through the medium as results of collisional and radiative processes. In 
bremsstrahlung process, the increasing number of kinetic energy and high atomic 
number (Z) material will increase the probability of radiation loss (Ajjitchandran, 
2008).  The electron interaction with the medium resulting in decrease in energy and 
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determine the characteristic of depth dose curve that give clinical benefit of electron 
beam.   
Electron beams are used to treat the tumour disease within approximately 6 
cm from the surface depending on the beam energy. Treatment of cancer such as skin 
and lips, upper-respiratory and tumour bed boost for breast cancer take advantages of 
electron therapeutic ranges. Dose delivery from the surface to a specific depth where 
the dose will fall off rapidly until the value is near to zero are particularly useful for 
variety of clinical situation (Ajjitchandran, 2008).   
 
1.1.3 Proton Beam Radiotherapy 
Proton was discovered in 1919 by Ernest Rutherford in an experiment 
conducted on the hydrogen nucleus that was extracted from nuclei of nitrogen by 
collision. The hydrogen nucleus was named as Proton, after the neuter singular of the 
Greek word for “first” (William, 2013). Proton is a subatomic particle with positive 
electric charge and mass slightly less than neutron but much heavier than electron 
(the proton is 1,836 times more massive than an electron). Proton interaction depends 
on their energy which represents the velocity. The interaction could be inelastic or 
elastic collisions with the nucleus, with the bound atomic electrons or with the whole 
atom. This interaction of proton with matter creates the basis for therapeutic potential 
of proton beam in cancer treatment and become an alternative treatment modality 
instead of photons (Mazal, 2007; Thomas, et al., 2009). 
Production of proton beams for medical used involve highly sophisticated 
accelerator facilities, beam transport system, shielding, beam shaping device , patient 
positioning system and the control system. Proton originally coming from the ion 
 8 
 
sources where hydrogen atoms are separated into the electrons and protons. The 
protons are ejected into the cyclotron where they were accelerated. High power of 
protons was sent through the energy selection system and degrader to determine and 
adjust the proton energy. The beam transport system will conduct the protons with 
right energy and their trajectory. Once the desired amount of energy is achieved, a 
magnetic field steers the protons into the treatment room through gantry. Gantry can 
rotates up to 360° and deliver beams at any angles. The beams move through the 
custom made devices called aperture and the compensator shapes the exact size and 
depth of the tumor. The proton beams deliver powerful therapeutic dose to the tumor 
with no exit dose which provides great advantages to the deep seated tumor. Figure 
1.3 shows the proton beam therapy machine (Hyogo Ion Beam Medical Center, 
Japan).  
 
 
Figure 1.3: Proton Beam Radiotherapy Machine 
 
The proton interaction creates a peak of the energy directly targeted into the 
tumor without unnecessary dose to the surrounding tissue (Mazal, 2007). Energy 
 9 
 
ranging between 65 to 250 MeV is normally employeddue to their depth dose 
properties and characteristic that is favourable for clinical application.  Charged 
particles proton beams have a very rapid energy loss after a few millimetres of 
penetration which results in Bragg peak. Bragg peak is a sharp and localized peak of 
dose. The penetration depth of the Bragg peak is determined by the initial energy 
(speed) of the charged particles. Desired dose can be delivered to anywhere in the 
patient’s body with high precision by adjusting the energy of the charged particles 
and intensity of the beam (Levin, et al., 2005; Thomas, et al., 2009). The Figure 1.4 
shows the graph of the Bragg Peak of proton beam therapy.  
 
Figure 1.4: The Graph of the Bragg Peak of Proton Therapy 
 
The interesting characteristics of proton beams depth dose provide superior 
spatial dose distribution to the tumour while reducing the total dose to critical organ. 
The dose delivered to tumour volume is more conformal and uniform which increase 
the therapeutic ratio of radiotherapy. The term of therapeutic ratio can be defined as 
the ratio of the probabilities for tumour eradication and normal tissue complication 
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and is often used to consider the balancing between administering the prescribed 
target dose and dose to healthy tissue.  
The proton beams have been clinically adopted to treat various types of 
cancer such as ophthalmic and intracranial malignancy, glioblastoma multiforme, 
artero-venous malformations and prostate carcinoma. Besides that, it is also able to 
treat tumors in the vertebral and paravertebral regions, central nervous system, lung 
and pelvic tumors (Mazal, 2007; Slater, 2006). Proton radiation therapy also could be 
used in combination with photon irradiation such as radiosurgery and stereotactic 
radiotherapy, surgery and chemotherapy. 
 
1.1.4 Synchrotron Radiation 
Synchrotrons radiations are electromagnetic radiations consist of the entire 
electromagnetic spectrum from radiowaves, infrared light, visible light, ultraviolet 
light, x-rays and gamma rays. Synchrotron radiations are generated when electrons 
moving at almost the speed of light in a curved trajectory under the influence of a 
circular magnetic field. The electromagnetic waves emitted have ranges of 
wavelengths from very low such as x-rays and some of much longer such as the 
visible light range. Synchrotron radiation has special characterization such as high 
intensity, brightness, directionality and variable polarisation, which is distinctive 
from clinical conventional x-rays.   
The synchrotron radiation produce artificially by synchrotron is the brightest 
man made x-rays source. Figure 1.5 shows the schematic diagram of the production 
of synchrotron radiation. The process begins when electrons are generated by 
electron gun through heating a barium compound cathode. The electrons are 
accelerated in a linear accelerator by electric field and it is accelerated even more by 
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means of a strong magnetic field until they reach the 99.999% of the speed of light. 
After that, electrons are transferred from the linear accelerator to the booster ring 
where their energy is augmented using radiofrequency (RF) energy. Dipole of 
electromagnets force is used to direct the electron path into circular trajectory. The 
electrons were then passed into the storage ring when they approximately complete 1 
million laps in half a second.  
The electrons accelerated at constant speed will remain in a circular orbit 
when they are injected into the storage ring. They will circulate for approximately 
30-40 hours and continuously emits intense synchrotron radiation. The synchrotron 
radiation from the storage ring is then transferred to the beamlines for the utilization 
in research and experimental work. Each beamline include different types of filters, 
mirrors and other optical components that prepare the radiation for application in 
different fields.  
 
Figure 1.5: The schematic diagram of the production of synchrotron radiation 
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Synchrotron radiation has several advantages compare to conventional 
clinical x-rays. Synchrotron radiation is special because of the intensity is extremely 
high which is brighter than the sun. The high level of intensity that synchrotron 
produce can reveal the details that cannot be seen using any other method. This 
allows the researcher to observe highly detailed and accurate image or information. 
Moreover, the radiation emitted covers a continuous, wide range of wavelengths 
simultaneously. The wavelength or range of wavelengths can be specifically selected 
according to the required specification of a research. The radiation light emitted is 
outside the visible spectrum, mostly from infrared to x-rays and it’s depends on the 
energy of the electrons. The visible light might be produced when the electrons travel 
the curve with lower energy; with higher energy they might produce x-rays. The 
synchrotron light beam is precisely focused, result in a very small divergence which 
allows extremely small areas of a sample to be investigated.  The results are superior 
in terms of accuracy, quality, robustness, the level of detail that can be seen and the 
amount time required to analyse a sample is extremely short.  
 Synchrotron radiation is applied many application in physics, chemistry, 
biology and medicine. In medical for instance, absorption contrast imaging is 
performed using synchrotron radiation. It is made possible to select a narrow 
wavelength band by crystal monochromator because of the high intensity and good 
natural collimation of synchrotron radiation. Besides that, synchrotron radiation is 
also used in coronary angiography and micro-angiography as diagnostic method 
which provides detailed high-resolution images. Another potential clinical 
applications using synchrotron radiation are mammography screening, micro-
tomography with spatial resolution of a few micrometres and computed tomography 
to eliminate the effects of beam hardening (Suortti, et al., 2003). Figure 1.6 shows 
 13 
 
the Australian Synchrotron situated in Clayton, Victoria. Some part of the 
experimental work in this thesis was performed using the Imaging and Medical 
Beamline, Australian Synchrotron. 
 
 
Figure 1.6: The Australian Synchrotron 
 
1.1.5 Comparison of Photon, Electron, Proton and Synchrotron Radiotherapy 
Radiotherapy employs different type of radiation beam such as photons, 
electron, proton and recently synchrotron radiation to treat cancer. Each type of beam 
has advantages and disadvantages that require great optimization in order to produce 
high conformal dose to the tumours and reduced dose to normal tissue.  
 Conventional external beams radiotherapy that use the high energy photons 
and electrons beams are the most commonly and widely used to treat the tumours 
cells. The megavoltage photon beams provide greater penetration or depth dose due 
to the lower mass attenuation coefficient of high energy x-ray (Stanton & Donna, 
1996). In clinical applications, 4-8 MV photon beams are the most useful for 
providing a balance between penetrations through tissues. Megavoltage photon 
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beams also provide skin sparing effects which can reduced the skin reactions towards 
radiation (Stanton & Donna, 1996; Peter Hoskin, 2006). Meanwhile, megavoltage 
electrons beam is widely used for superficial tumours due to the depth dose 
characteristic that to deposit the energy immediately on entering the patient. 
 Proton beam radiotherapy provide different alternative in cancer treatment. 
Proton have dense ionization region which is called Bragg Peaks. Heavy charged 
particles penetrate the tissue and steadily increase the linear energy transfer (LET) to 
the maximum. The increase of the LET produce more dense ionization near the end 
of their path compare to the beginning which produced the Bragg peaks. Compare to 
the photon beam, proton beams have no exit dose which could reduce the normal 
tissue complication. Highly conformal dose distributions can be achieved and less 
normal tissues dose can be achieved. This allows the proton therapy for better acute 
tolerance of combined chemotherapy and radiation therapy (Levin, et al., 2005).  
  
 
Figure 1.7: The graph of dose versus depth for megavoltage photon, electron and 
proton beams 
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The Figure 1.7 shows the graph of depth dose for megavoltage photon, electron 
and proton beams. The depth dose curves of electron beams contrast sharply with the 
photon beams when the electron beams’ depth dose fall rapidly compared to the 
photon beams. The depth dose characteristics of protons are enticing because of their 
high dose at depth and very tiny doses at the beginning and the end of the peak. In 
real clinical cases, majority tumours are larger than the Bragg peaks and more useful 
Bragg peak width can be produce by spreading the particle energy (Stanton & 
Donna, 1996).  
 
1.2 Radiobiological Aspect in Radiotherapy  
Radiobiological effect occurs with the combination actions of both ionizing 
radiation (photon and electron) and biological human cell.  The charged particles 
absorbed in the human cell interact directly with the important component of the 
DNA strands. The interaction causes the biological effects which is cell death. The 
clinical biology focused on the relationship of absorbed dose and biological 
response. Radiobiological modelling is used for quantitative radiation biology that 
will explain both dose-response and time-dose relationships. Radiobiological 
modelling are used to predict the outcome of radiation therapy based on dose 
distribution characteristics. The radiobiological model used in this study is Linear 
Quadratic model (LQ model).  
 
1.2.1  Linear Quadratic Model  
Linear quadratic model is the models that commonly used to analyse 
radiation response of both in-vitro and in-vivo data. LQ model is commonly and 
widely used to describes the cell killing in terms of DNA double strand breaks 
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(DSBs) produced by the radiation with the proportionate to the dose. The DSBs may 
be repaired with different rate constants and LQ is one of them (Brenner, 2008). The 
LQ model describes the relationship between cell survival and irradiation dose, based 
on this formula:
 
                                      S = exp
– (αD + βD2)
     (1) 
 
Where S is the survival, α and β are dependents and D is the absorbed dose. 
In the other word, the LQ model assumes that S is made of two terms; a linear term, 
αD and a quadratic term, βD2.  
 The LQ model is accurate in the fractionation region from 1.5 to 4 Gy. 
However, the accuracy becomes less as the range of the radiotherapy application 
widen with the classical LQ model (Brahme, 2011). The LQ model is not suitable at 
the high dose region where it underestimates the surviving fraction in the high dose 
range. The parameter of the model is essential. However, realistic model is more 
desirable to describe more complex treatment (Andisheh, et al., 2013).   
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1.3 Problem Statement and Rationale of the Study 
Radiotherapy in conjunction with chemotherapy and surgery is the primary 
option for cancer treatment. High energy ionizing radiation is delivered to the 
tumours site with high accuracy and precision to induce cellular damage and DNA 
breakage of cancer cells. Despite the technological advancement in radiotherapy 
technique, the curative potential of radiotherapy is always restricted by normal tissue 
tolerance and the tumour cell resistance. This constraint impales the therapeutic 
efficacy of radiotherapy to remain dismal.   
Gold nanoparticles have been extensively investigated to increase the cancer 
cell radiosensitivity but to date no clinical application of gold nanoparticles have 
been approved. IONPs have been clinically applied as contrast agent for MRI and 
widely studied for other promising biomedical application. Application of IONPs as 
dose enhancer in radiotherapy is not widely explored and their therapeutic potential 
are still unknown.  The advantages of IONPs over AuNPs such as magnetic 
properties, biocompatibility and cost effectiveness could have benefits radiotherapy 
especially for hypoxic and radioresistant tumours.  
In this study, the potential of IONPs as novel radiation dose enhancer for 
radiotherapy was investigated. The applicability of IONPs as radiation dose enhancer 
was evaluated with wide range of radiotherapy beam from conventional megavoltage 
x-ray beam to monoenergetic kilovoltage x-ray beam, electron beam and proton 
beam. This thesis present novel results of the radiobiological effects induced by 
ionizing radiation with augmented impact by IONPs that could be promising for 
radiotherapy cancer patient.  
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1.4 Aims of the Study 
To investigate the dose enhancement effects by the Iron Oxides Nanoparticles 
(IONPs) using different types of radiotherapy beams.  
 
1.5 Objectives of the Study 
i. To assess the cytotoxicity of IONPs. 
ii. To quantify the dose enhancement effects produced by IONPs for photon, 
electron, proton and monoenergetic kilovoltage x-ray synchrotron beam. 
iii. To evaluate the radiobiologic characteristic of in vitro cell survival curves in 
the presence of IONPs using LQ model.  
iv. To analyze the effect of IONPs elemental molar concentration to the radiation 
dose enhancement effects.   
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Nanomedicine in Radiotherapy 
Nanometer size materials had a big impact on many scientific fields and area 
including medicine. This has fascinate scientist into exploring the possible 
application of nanomaterials in various field especially medicine. Nanoparticles are 
defined as nanostructures consisting of a number of atoms or molecules in the 1-1000 
nm diameter range in at least one dimension. They are believed to have specific 
advantages over conventional drugs in the treatment of diseases and are used for 
various biomedical applications where they facilitate laboratory diagnostics and 
treatment of diseases, especially cancer (Mahmoudi, et al., 2010). 
In radiotherapy, nanoparticles have potential application as radiosensitizer in 
enhancing the efficacy of the treatment. There are many types of the radiation 
sensitizers that are grouped in metal-based nanoparticles, quantum dots, 
superparamagnetic iron oxides and non-metal based nanoparticles. Examples of 
metal-based nanoparticles are the gold nanoparticles (AuNP), Gadolinium based 
nanoparticles (Gd-NP), Titanium based (Ti-NP), Silver based nanoparticles (Ag-NP) 
and Hafnium-based nanoparticles (Hf-NP). The non-metal based nanoparticles can 
be classed as Silicon-based nanoparticles (Si-), Fullerene-based nanoparticles and 
chemotherapeutic entrapped nanoparticles (Kwatra, et al., 2013).  
Currently, a large number of nanoparticles have been synthesized especially 
those made from noble metals such as gold (Thakor, et al., 2011). In previous and 
recent studies, gold are mostly used as laboratory based clinical diagnostics imaging 
agent or therapeutic agent. Gold have high atomic number (Z=79) and very inert to 
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tissue interaction. These characteristics makes gold ideal for photoelectric 
interaction. The interaction of x-rays with high Z nanoparticles results in the 
development of the concept where the efficiency for radiation mediated cellular 
damage could be elevated. In one of the study conducted using AuNPs, a significant 
dose enhancement effect upon irradiation were observed in cell culture. In another 
the study using AuNPs with ~ 3 µm sizes, less cell growth were observed after 
irradiation. Dose enhancement effects however depend on many factors such as 
particles size and localisation inside cells. Larger particles have problem with lack of 
diffusion in cancer tissue. Small size nanoparticles have been extensively optimized 
and utilized in various cancers treatment (Kwatra, et al., 2013).  
AuNPs have many beneficial attributes such as easy to synthesis, 
functionalization and shape control that frame this type of nanoparticle as an 
attractive target for further development (Thakor, et al., 2011). Gold are very inert 
and highly biocompatible. The AuNPs are well absorbed into the systemic 
circulations and tumour tissue due to the AuNPs properties that have low systemic 
clearance compared to low molecular contrast agent such as iodine. AuNPs also 
could be specifically delivered to the tumour tissue by attaching the nanoparticles to 
the targeting moieties such as antibodies. 
In contrast to the bulk materials, nanoparticles can be designed to contain 
thousands of atom in one particles. This important property potentially could 
increase the radiation interaction cross section at the target.  Therefore, AuNPs of 
various sizes and shapes can deliver optimum dose to the tumour tissue based on the 
delivery requirements such as the tumour size and location (Kwatra, et al., 2013).   
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Other than AuNPs, metal nanoparticles such as gadolinium nanoparticles are 
also identified as one of the radiation sensitizers. Gadolinium nanoparticles are very 
practical because they could be easily view in vivo through magnetic resonance 
imaging (MRI). Gadolinium also can generate long-lived pi-radical cations during 
exposure to hydrated electrons (Kwatra, et al., 2013). An in vitro study on the 
effectiveness of Gadolinium on HT-29 cells found that the Gadoliniums are effective 
either in vivo or in vitro study. A new class of radiosensitizer detectable by MRI, 
Gadolinium (III) texaphyrin is being developed for imaging and therapeutic purpose 
(Young, et al., 1996).   
Material such as titanium dioxide (TiO2) is a common semiconductor material 
that is widely used for oxygen detection in environmental gas sensor. This TiO2 
material is somehow found it usefulness in killing cancer cells via photocatalytic 
chemistry. The activation of the TiO2 by x-rays resulted in the formation of reactive 
oxygen species (ROS) which enhanced photoelectric effects in vivo. TiO2 nanotubes 
were formulated and tested for their radiosensitization effects of glioblastoma 
because the elongated organic nanoparticles are internalize into the cells more 
effectively compare to spherical shapes. A study done by Mirjolet, et al., (2013) 
found that the TiO2 nanotubes are very effective radiosensitizers in SNB-19 and 
U87MG cells by enhancing the DNA damage and retarding the DNA repair. 
Petkovic, et al., (2011) has conducted a study on pre-photoactivated TiO2 
nanoparticles using HepG2 cells and observe the cytotoxic effects are enhanced by 
induction of double stranded breaks.  
Silver nanoparticles (AgNPs) have similar radiosensitizing and 
physicochemical properties as AuNPs and hence utilized similar mechanisms for 
radiosensitization effects like other high Z-number atoms. AgNPs are more cost 
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effective compare to AuNPs and relatively less biocompatible (Coulter, et al., 2013; 
Kwatra, et al., 2013). Previous studies confirmed that AgNPs had obvious anti-
tumour capabilities when tested in-vitro which make it attractive for radiotherapy 
application. Different types of AgNPs have been synthesis and studied for their 
radiosensitizing activity. Multiple different coatings AgNPs combined with 
radiations in glioma cell lines shows the possession of anticancer properties (Xu, et 
al., 2009; Kwatra, et al., 2013). For examples, chitosan-coated triangular AgNPs 
shows better radiosensitizing effects compare to conventional poly-(ethylene) 
glycolcapped (PEG) coated AuNPs on human non-small lung cancer cells (Boca, et 
al., 2011; Kwatra, et al., 2013).   
Unique high Z-elements such as hafnium oxide (HfO2) are uncommon but 
some studies show potential of this type of nanoparticles as dose enhancer agent in 
radiotherapy. HfO2 nanoparticles have been tested in HCT116 cell lines in vitro and 
it show reaction towards photo-luminescent properties which cause thermal induced 
stress damage to cellular components. Significant radiosensitization effects have 
been observed with HfO2 nanoparticles as well as good biodistribution properties and 
excellent biocompatibility (Maggiorella, et al., 2012; Kwatra, et al., 2013).  
Iron oxide nanoparticles (IONPs) have been traditionally used for disease 
imaging and it is recently used for cellular-specific targeting, drug delivery and 
multi-modal imaging (Veiseh, et al., 2010). IONPs are a magnetic nanoparticles that 
represent a class of non-invasive imaging agents that have been developed for 
magnetic resonance imaging (MRI) and currently the only types of nanoparticles that 
have been approved for clinical study (Mahmoudi, et al., 2009). IONPs with 
appropriate surface chemistry have been widely used for in vivo applications such as 
magnetic resonance imaging contrast enhancement, tissue repair, immunoassay, 
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hyperthermia, drug delivery and radiotherapeutic purpose. Details of IONPs 
properties will be discussed in the next section. 
 
2.2 Iron Oxide Nanoparticles (IONPs) 
Among all types of nanoparticles, IONPs are special in their superparamagnetic 
properties which allow them to be directed and localized to a particular organ using 
external magnetic force. IONPs with proper surface architecture and conjugated 
targeting ligands/proteins have attracted a great deal of attention for drug delivery 
applications (Mahmoudi, et al., 2010). IONPs are highly biocompatible with 
negligible toxicity to healthy tissues which make them suitable for therapy 
application (Kwatra, et al., 2013).  
Naked IONPs are quite unstable and even form bulk aggregates in biological 
fluids. So, appropriate design of core and shell of IONPs is extremely important for 
medical applications (Li, et al., 2013). Plunoric F-127-coated iron oxide 
nanoparticles have been developed for application as MRI contrast agent and also 
anti cancer therapies. These NPs have relatively higher T2 relaxivity and capable to 
accommodate high payloads of multiple drugs. The drug released from iron oxide 
NPs is effective in killing cancer cells (Wajadkar, et al., 2013). Studies also found 
out that IONPs are able to inhibit the function of the receptor to induce apoptosis in 
glioma cells in vitro (Kievit, et al., 2011). 
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2.2.1 Types of IONPs 
Iron Oxide nanoparticles (IONPs) exist in variety of structures and 
characteristic. Ferrous and ferric iron oxides were presented in seven phases of 
crystalline. The most common were hematite, maghemite, magnetite and wustite. 
IONPs have been used in many applications. In examples, magnetite NPS have been 
used in cancer diagnosis and therapy and maghemite is used in magnetic resonance 
imaging (MRI) (Martinez, et al., 2009). 
 
2.2.2 Properties of IONPs 
i. Magnetic properties 
Iron oxide nanoparticles exhibit paramagnetism and diamagnetism properties 
and are classified by their response to an external magnetic field (Gupta, et al., 
2005). Different types of magnetism can be identified based on the orientation of 
magnetic moments in a particle which depend on the magnetic induction; B on the 
magnetic field, H. Iron oxide nanoparticles also shows ferromagnetism properties in 
which it can be permanently magnetized.  
One of the important advantages of magnetic nanoparticles is their 
superparamagnetism. Superparamagnetic iron oxide nanoparticles (SPIONs) are 
potentially applied for biomedical applications such as magnetic drug targeting, 
enhanced resolution magnetic resonance imaging and cell targeting. SPIONs are 
useful as drug delivery agents because the SPION can be transported by magnetic 
field to desired site (Mahmoudi, et al., 2009).The SPION will remains at the target 
for a certain period of time once the external magnetic field is removed (Gupta, et al., 
2005; Mahmoudi, et al., 2009).  
